SomaLogic, OncoHost announce license agreement for the development of precision cancer diagnostics

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

SomaLogic and OncoHost signed a licensing agreement, through which OncoHost will license SomaLogic’s SomaScan Platform to develop proteomics tests for its PROphet diagnostic system, designed to predict patients’ response to immunotherapy treatments and provide strategies to overcome treatment resistance. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login